Figure S4 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity

A, Combination treatment of XTC.UC1 with rapamycin and the pan-AKT inhibitor MK2206 and MEK inhibitor PD325902. B, Cell proliferation assay of XTC.UC1 cells treated with rapamycin or AZD8055 alone and in combination with MK2206 or PD325902. C, Immunoblot analysis of mTOR signaling at 5 hours after treatment with rapamycin or AZD 8055 alone and in combination with MK2206 or PD325902. Rapamycin combined with MK2206 did not further reduce cell proliferation, despite inhibition of p-AKT(S473). Rapamycin combined with PD325901 did not result in further reduction of cell proliferation.